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aripiprazole (RR:1.29, 95%CI:1.05–1.58), haloperidol (RR:1.29, 95%CI:1.03–1.62). 
Lithium followed by divalproex ER were the most effective mood stabilisers: lithium 
(RR:1.73, 95%CI:1.08–2.79), divalproex ER (RR:1.40, 95%CI:1.09–1.80), dival-
proex (1.12, 95%CI:0.81–1.55), carbamazepine ER (not available). The results 
for response reported that risperidone and quetiapine XR were the most effective 
antipsychotics: risperidone (RR:1.77, 95%CI:1.50–2.09), quetiapine XR (RR:1.61, 
95%CI:1.23–2.10), olanzapine (RR:1.54, 95%CI:1.23–1.92), aripiprazole (RR:1.46, 
95%CI:1.26–1.70), haloperidol (RR:1.41, 95%CI:1.19–1.66). Carbamazepine ER 
followed by lithium were the most effective mood stabilisers: carbamazepine ER 
(RR:2.01, 95%CI:1.55–2.61), lithium (RR:1.57, 95%CI:1.28–1.92), divalproex 
(RR:1.46, 95%CI:1.10–1.93), divalproex ER (RR:1.45, 95%CI:1.12–1.87). Due 
to incomplete reporting, the pooled mean difference in YMRS was considered 
unreliable. CONCLUSIONS: Selecting the right pharmacological treatment strategy 
which optimises remission is key to maximising patient outcomes and efﬁcient use of 
health care resources. This analysis suggests that risperidone, quetiapine XR and 
lithium are promising treatment options for bipolar I mania. 1. Smith, Bipolar Disord. 
2007;9:551–560.
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OBJECTIVES: When compared to the general population, people with severe         
mental disorder (SMD) more commonly show obesity, sedentary lifestyles and 
poor dietary choices. This review examines the effectiveness and cost-effectiveness of 
lifestyle interventions on physical activity and dietary choices in people with 
SMD. Included health outcomes were changes in weight, body mass index (BMI) 
and quality of life. METHODS: A systematic E-search strategy was conducted      
using Medline, Web of Science and CINAHL to select articles of lifestyle interventions 
targeting exercise and dietary choices in people with SMD. In addition, the reference 
lists of retrieved articles from the E-databases were hand-searched. RESULTS: 
The search strategy produced 14 randomized and non-randomized comparative trials 
that met the inclusion criteria. Mean duration of the interventions was 20.0 o 10.84 
weeks. Weight loss was reported in 11 studies, with a mean weight change of 1.96 
o 1.84 kg in the intervention groups versus 1.77 o 2.12 kg in the control groups.      
Changes in BMI were 0.87 o 0.69 kg/m² and   0.64 o 0.96 kg/m² respectively in    
intervention and control groups. Differences in changes in weight and BMI between 
intervention and control groups were statistically signiﬁcant in nine studies. The results 
also suggest that quality of life and general health could beneﬁt from these kinds of 
interventions. For example, subjective improvements in quality of life (p  0.047) and 
in overall health (p  0.023) were found in the study of Evans et al. (2005). In 
none of the studies, however, cost-effectiveness was examined. CONCLUSIONS: 
Small weight loss through lifestyle interventions targeting physical activity and 
dietary choices is possible in people with SMD. This is promising given the high 
prevalence of sedentary lifestyles and poor dietary choices and the effects of some 
atypical antipsychotics on weight gain. Further study of both effectiveness and cost-
effectiveness (including the most cost-effective ‘dose’) of lifestyle interventions in 
people with SMD is required.
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OBJECTIVES: To explore differences between age subgroups in QOL in atomoxetine 
treated patients and evaluate correlations between ADHD core symptoms and QOL. 
METHODS: Pooled data of 5 similar clinical atomoxetine trials (8–12 weeks follow-
up, 3 placebo-controlled, 2 open-label) were included in the analysis. All studies used 
the ADHD-RS and the CHIP-CE instruments. Treatment group differences (effect size 
vs. placebo) in CHIP-CE score changes were compared between different age groups 
( /&GE;12YRS);  RESULTS: A total of 611 children (12 yrs) and 183 adolescents 
(q12 yrs) were included. Baseline CHIP-CE total t-scores (mean o SD; norm: 50 o 10) 
were similar in children (29.3 o 11.58) and adolescents (27.5 o 12.29) (p  0.296). 
Greater impairments in the CHIP-CE ‘achievement’ domain were seen in adolescents 
than children (t-scores 31.0 o 10.26 and 28.9 o 10.71, respectively; p  0.05); there 
were no clinically relevant differences in other domains. For the CHIP-CE ‘risk avoid-
ance’ domain, the effect size of atomoxetine was higher in adolescents than in children 
(0.83, p  0.001 and 0.37, p  0.005; age*treatment interaction p  0.059); age group 
differences for other domains and CHIP-CE total scores were not clinically relevant. 
ADHD-RS/CHIP-CE correlations were low at baseline but moderate for change 
from baseline being similar in age groups. Only the ‘risk avoidance’ domain showed 
a trend towards lower correlation of change in adolescents (r  0.384 and r  0.545). 
CONCLUSIONS: Both age groups showed a clinically relevant impairment of QoL 
at baseline which was similar for adolescents and children in four out of ﬁve CHIP-CE 
domains. In both groups, atomoxetine was effective in improving QoL. For the ‘risk 
avoidance’ domain, the effect size of atomoxetine was larger in adolescents than in 
children, while the ADHD-RS/CHIP-CE correlation was lower in adolescents, indicat-
ing a lower association with core symptoms.
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OBJECTIVES: The objective was to compare occurrence of relapse according to 
antipsychotic treatment (monotherapy vs polypharmacy), in a 2 year observational 
cohort of 288 French schizophrenic patients, using different methods of adjustment. 
METHODS: Relapse was deﬁned by a usual, clinically well reproducible and validated 
deﬁnition. The occurrence of relapse between patients receiving one antipsychotic to 
patients receiving more than one antipsychotic was compared according to a Cox 
model including or not the propensity score (PS). The propensity score was calculated 
on socio-economic and demographic information, clinical variables, quality of life, 
medication information and attitude toward treatment. Cox models were built accord-
ing to four usual methods to calculate the propensity score: 1—stepwise PS, continu-
ous, 2—non stepwise PS, continuous, 3—non stepwise PS, quintiles 4—non stepwise 
PS quintiles used to stratify the sample. We also used standard adjustment using all 
variables included in the model estimating the PS. Likelihood, Akaike’s information 
criterion (AIC) criterion and Schwatz’s Bayesian Criterion (SBC) criterion were used 
to compare the models. RESULTS: The standard cox model reports signiﬁcant 
decrease of relapse in patient receiving polytherapy. Consistently the four models 
based on propensity scoring methods did not ﬁnd any difference between the two 
populations. The model that optimizes all criteria (2logL, AIC and SBC) is the model 
using the stratiﬁcation on the propensity score. CONCLUSIONS: Polytherapy is not 
associated to a reduction of relapse while consistently literature reports major risk 
associated to polypharmacy including increased mortality. The use of propensity 
scoring is well established for observational data and this study illustrate that standard 
regression could be misleading.
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OBJECTIVES: To evaluate time to optimization of dose in children with ADHD in 
The Netherlands. METHODS: Claims data from the PHARMO medical record 
linkage system database from 48 geo-demographic areas in The Netherlands (2003–
2006) were analyzed from newly treated ADHD patients aged 6–17 years. Patients 
were followed for at least 12 months after treatment initiation with methylphenidate 
or atomoxetine. Demographic and medication characteristics at treatment initiation, 
and concurrent psychotropic treatments in the year before ADHD treatment initiation 
were recorded. For this analysis, only patients with ³5 dispensings for any ADHD drug 
during follow-up and no missing information on type of drug, strength, and number 
of pills per day were included. Optimized dosing regimen was deﬁned as no change 
in type of drug, strength, and number of pills per day for 5 consecutive dispensings 
(no time restriction between dispensings). Time to optimized dosing regimen was 
deﬁned as the number of days between the ﬁrst dispensing for an ADHD drug (cohort 
entry date) and the ﬁrst of ﬁve unchanged dispensings. RESULTS: Of 4909 children 
initiating treatment from 2003–2006, 3159 met selection criteria. The proportion of 
patients reaching dosing optimization with initial treatment was 69.8% for atomox-
etine (ATX; n  37), 74.8% for short-acting methylphenidate (SA; n  2017), and 
82.4% for long-acting methylphenidate (LA; n  262; P  0.05 for both ATX and SA 
vs LA). The median number of days required to reach optimal dosing regimen was 
49 across the total sample. Among patients achieving dose optimization, those initiat-
ing treatment with LA had a signiﬁcantly shorter time to dose optimization (14 days) 
than patients initially treated with SA (56 days; P  0.001) or ATX (31 days; 
P  0.05). CONCLUSIONS: Time to optimization of dosing regimen in children 
with ADHD in The Netherlands varied according to treatment chosen at initiation 
and was shortest for long-acting methylphenidate. Supported by funding from Shire 
Development Inc.
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OBJECTIVES: Alzheimer’s disease is an irreversible progressive disease that affects 
cognitive, behavioural and functional abilities. The prevalence of Alzheimer’s disease 
is increasing as the world’s population is aging. The primary aim of the study was to 
determine the prescribing patterns and cost of drugs for Alzheimer’s disease in a 
private health care sector patient population. METHODS: A retrospective, exposure-
cohort pharmacoepidemiological study was conducted. Data were obtained from a 
South African private pharmacy group for 2008. The database consisted of 1,578,346 
medicine records. RESULTS: A total of 588 patients (326 females and 262 males) 
received 2623 medicine items for Alzheimer’s disease at a cost of R1,563,701.18 
(average cost per item R596.15). The average age of patients was 75.54 (SD  10.48) 
years, with 78.40% of patients between 70 and 89 years of age. Donepezil was the 
most frequently prescribed active ingredient (37.09%), followed by galantamine 
(36.94%). Donepezil accounted for 39.50% of the cost of Alzheimer medication. No 
notable differences in prescribing patterns were observed over the 12-month period. 
